AMGN$327.865
Chart
Performance
Key Stats
AI AMGN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAmgen demonstrates strong fundamental performance with solid profitability and a robust balance sheet. Thematic tailwinds are positive, although technical indicators suggest a consolidation phase. Overall, a promising long-term investment with potential for short-term volatility.
Thematic
Amgen benefits from strong positioning in the biotechnology and pharmaceutical sectors, with significant growth drivers in its product pipeline and therapeutic areas. The company's focus on innovation and unmet medical needs provides a positive thematic outlook.
Fundamental
Amgen exhibits strong financial health with a solid revenue base, consistent profitability, and a manageable debt level. Free cash flow generation is robust, supporting dividend payouts and reinvestment.
Technical
The stock is trading in a generally upward trend, with most moving averages indicating a bullish sentiment. However, some oscillators are approaching overbought levels, suggesting a potential for a short-term pause or consolidation.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Aging Population | 80 |
| Chronic Disease Management | 82 |
| Healthcare Policy & Regulation | 70 |
| Biosimilars and Competition | 73 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 85 |
| Growth | 75 |
| Balance Sheet Health | 70 |
| Cash Flow | 80 |
| Dividend | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 60 |
| Volume | 70 |
| Support and Resistance | 65 |
| MACD | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Earnings Momentum
Multiple quarters show reported EPS exceeding estimates, with significant positive surprises (e.g., 13.97% in 2025 Q2, 9.11% in 2024 Q4), indicating consistent earnings power and potential for upward revisions.
Reasonable P/E for Growth
The trailing P/E ratio of 28.10 is supported by EPS TTM of $10.98. While not low, the historical performance and future earnings potential (as indicated by positive EPS surprises) may justify this valuation.
Bearish Points (7)
High Quarterly P/E Ratios
Several quarterly P/E ratios are exceptionally high (e.g., 96.0 in Q1 2025, 219.8 in Q4 2024, -1468.2 in Q1 2024), indicating that current market prices may be significantly ahead of current earnings, suggesting potential overvaluation on a short-term basis.
Fluctuating Revenue Growth
While annual revenue showed growth from 2021-2024, the quarterly revenue data shows significant volatility, with Q4 2024 revenue at $9.086B and Q1 2025 projected at $8.149B, and reported Q1 2024 revenue of $7.447B. The net margin in Q4 2024 dropped significantly to 6.9% from 33.3% in Q3 2024, indicating potential margin pressures.
Calendar
May 2025
16
Ex-Dividend Date
June 2025
6
Next Dividend Date
August 2025
6
Next Earnings Date
H: $5.84
A: $5.27
L: $4.81
H: 9.32B
A: 8.91B
L: 8.62B
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Seasonals
Price Target
314.45 USD
The 39 analysts offering 1 year price forecasts for AMGN have a max estimate of 400.00 and a min estimate of 185.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor across multiple therapeutic areas including immunology (Humira vs. Amgen's Enbrel), oncology, and neuroscience, with significant market overlap.
Weight: 95
Through its subsidiary Genentech, Roche is a major global competitor in oncology, immunology, and neuroscience, key therapeutic areas for Amgen.
Weight: 92
Major pharmaceutical competitor with a strong presence and significant pipeline in oncology and immunology, directly challenging Amgen's key product areas.
Weight: 90
Prominent biotechnology peer with competitive products in inflammation, eye disease, and oncology, often vying for market share with Amgen.